[ad_1]
Boehringer Ingelheim invests over 200 million euros in vaccine production in France for regulatory control of animal diseases
- This represents a record investment in the
animal health production network of the United States. - increase in world demand
preparations to combat foot-and-mouth disease and bluetongue - Boehringer Ingelheim will create about 100 new skilled jobs at the new site.
Boehringer Ingelheim has invested more than 200 million euros a new strategic production center for veterinary public health (German: official control of animal diseases) has been announced. The new facility will open in the French Rhône-Alpes region, known for its production of vaccines under the name of Vaccine Valley. This investment will enable Boehringer Ingelheim's Animal Health Division to meet the growing global demand for foot-and-mouth disease and bluetongue medicines.
"This is a record investment in our production network," said Veronique Kodjo. Head of Global Production for Animal Health at Boehringer Ingelheim. "The new location is an important pillar of our future growth strategy."
Boehringer Ingelheim creates about 100 new skilled jobs at the new site. The foundations of the 15,000 m2 high tech facility will be laid in the fall of 2018 and should be operational by the end of 2021.
"This project consolidates Boehringer Ingelheim's position as a scientific, industrial and commercial leader in the veterinary world Public health – measures taken by the government to control and eradicate outbreaks in livestock, "said Jacques Bonin, head of global veterinary public health at Boehringer Ingelheim "We are the main partner of governments and private customers in this area. Our goal is to be able to better help our customers in the fight against future diseases.
The commissioning of the new plant will enable Boehringer Ingelheim to set up antigen banks in particular. These are strategic vaccine pools that can be quickly activated by the state in the event of an outbreak.
The formulation of antigens and their filling in vaccine bottles is carried out on the neighboring site of Lyon Portes-des-Alpes (Saint-Priest). This site has also recently received a total investment of 135 million euros for the construction of a new Research and Development Center, which will be inaugurated in the autumn of 2018. The investment will also serve to set up a new vaccine formulation and filling facility for poultry, which will be operational in the spring of 2020.
In addition, Boehringer Ingelheim launched a joint venture early in the year to develop and produce vaccines against the mouth. NOTICE
Foot and mouth disease is a viral disease in livestock, which is prevalent mainly in parts of Asia, most of Africa and the Middle East. The highly contagious disease, but not transmissible to humans, causes significant economic losses for farmers. For this reason, the fight against this disease is high on the list of priorities of the World Organization for Animal Health (OIE).
Bluetongue is transmitted by insects. It is a non-infectious viral disease that mainly affects sheep. Cattle, goats and other grazing animals may also become ill. Bluetongue disease causes growth inhibition in sick animals and sometimes even death.
[ad_2]
Source link
